1)  PML/RARα
PML/RARα
1.
Detection of PML/RARα Gene Transcripts in 46 Newly Diagnosed Acute Promyelocytic Leukemia Patients by Real-time Quantitative Reverse-Transcription Polymerase Chain Reaction;
实时定量PCR检测46例初诊急性早幼粒细胞白血病患者PML/RARα mRNA的分子表达
2)  PML-RARα
PML-RARα
1.
The change of thymic nave T cells in BALB/c mice after immunization with PML-RARα-hIL-2 DNA vaccine;
PML-RARα-hIL-2 DNA疫苗免疫BALB／c小鼠后胸腺初始T细胞水平变化
2.
Immune response induced by reconstructed PML-RARα-hIL-2 plasmids in BALB/c mice;
PML-RARα-hIL-2 DNA疫苗诱导BALB／c小鼠的细胞和体液免疫应答
3.
Study on construction and expression of the eukaryotic coexpression plasmid containing PML-RARαgene and human IL-2 gene;
pIRES-PML-RARα-hIL-2重组质粒的构建和表达研究
3)  PML-RARα gene
PML-RARα基因
1.
Aim: To construct a eukaryotic coexpression plasmid containing PML-RARα gene and human GM-CSF(hGM-CSF) gene,which was expected to be used as a modified DNA vaccine for acute promyelocytic leukemia.
目的:构建急性早幼粒细胞白血病(APL)PML-RARα基因与人粒巨噬细胞集落刺激因子(hGM-CSF)基因真核双表达载体,为利用DNA疫苗治疗APL奠定基础。
2.
Objective To construct the PML-RARα gene recombinant plasmid, which is expected to be used as a modified DNA vaccine for acute promyelocytic leukemia.
目的构建PML-RARα基因重组表达质粒,为发展PML-RARα基因疫苗提供实验依据。
4)  PML-RARα peptide
PML-RARα多肽
1.
Objective To investigate the specific cytotoxicity of T cells from cord blood induced by PML-RARα peptide and NB4 cells in vitro.
目的了解PML-RARα多肽和NB4细胞体外诱导体外诱导增殖的T细胞的特异性细胞毒作用。
5)  PML/RARα isoform
PML/RARα异型
1.
To evaluate the relation of PML/RARα isoforms in adult APL patients to clinical therapy and prognosis, the picture of blood and bone marrow aspirates for 71 APL patients treated by induction therapy were peridically examined and the different transcripts of PML/RARα were assayed by nested RT-PCR.
为评价急性早幼粒细胞白血病(APL)PML/RARα异型与临床治疗及预后的相关性,对71例诱导治疗的APL患者定期进行血像、骨髓像检查,用巢式RT-PCR检测PML/RARα不同转录本。
6)  PML/RARαfusion gene
PML/RARα融合基因
1.
Methods FISH was used to detect the AML1/ETO fusion gene and/or PML/RARαfusion gene in 10 AML-M_2 cases,19 AML-M_3 cases and 11 AML cases undetermined as AML-M_2 or AML-M_3 by routine morphology,cytochemical staining and immunophenotyping.
方法对初发的经骨髓常规形态学、细胞化学染色和免疫分型初步诊断的10例AML-M2、19例AML-M3,11例AML不能确定为M2或者M3的患者,进行FISH技术检测AML1/ETO和/或PML/RARα融合基因,进而协助诊断和指导治疗。
参考词条
补充资料：α,α,α,α',α',α'-六氯对二甲苯
分子式：C8H4Cl6
分子量：312.84
CAS号：68-36-0

性质：白色针状或粉末状结晶。熔点108-110℃。溶于二甲苯、石油醚、乙醇、植物油，不溶于水。无味，有特殊臭味，遇光、碱会缓慢分解而呈酸性。

制备方法：以混二甲苯为原料，先用98%硫酸磺化，使间二甲苯生成间二甲苯磺酸盐。从磺化反应物中分离出含邻、对二甲苯的油层，水洗、干燥，减压蒸馏出邻、对二甲苯。间二甲苯磺酸盐经水解可得副产品间二甲苯。由邻、对二甲苯经氯化即得1，4-双（三氯甲基）苯：在反应锅中投入邻、对二甲苯，再加入过氧化苯甲酰和三乙醇胺。加热到70℃后，在光照射下导入氯气，于70-80℃反应6h，再升温至100-120℃继续反应，至反应液相对密度达到1.560-1.580（65℃），即为反应终点，停止通氯，减压脱除余氯。降温至5℃，过滤，洗涤得粗品，重结晶，活性炭脱色得成品。

用途：抗血吸虫病药物。对肝吸虫病、阿米巴原虫病、疟疾以及肠道线虫有一定疗效。但对神经系统的不良反应较多见，且延迟反应持续较久。

说明：补充资料仅用于学习参考，请勿用于其它任何用途。